Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. develops and commercializes medical devices for pediatric orthopedics, with products used in trauma and deformity, scoliosis, sports medicine and related procedures. Company news commonly covers quarterly financial results, revenue by product category, domestic and international sales trends, cash-flow metrics and updates to financial guidance.
Recurring product and market updates include specialty bracing, spine and deformity correction systems, implants, instruments and enabling technologies for pediatric care. Announcements also include investor conference participation and portfolio additions such as hospital-based traction systems and other products aimed at children with orthopedic conditions.
OrthoPediatrics (Nasdaq: KIDS) will participate in two investor conferences in March 2026 with fireside chats on March 3 and March 10. An audio webcast will be available on the company's investor relations site, with a replay available for 90 days after each event.
OrthoPediatrics (Nasdaq: KIDS) reported record full year 2025 revenue of $236.3 million, up 15% year-over-year, and fourth quarter 2025 revenue of $61.6 million, up 17% year-over-year. The company achieved full year adjusted EBITDA of $14.8 million and generated positive free cash flow of $9.8 million in Q4, its first quarter of positive free cash flow. Management reiterated 2026 guidance: revenue of $262.0–$266.0 million (+11% to +13%), adjusted EBITDA of $25 million, and breakeven free cash flow.
Q4 gross margin improved to 73.2%, net loss narrowed to $10.1 million for the quarter and full year net loss was $39.6 million. Cash and short-term investments totaled $62.9 million at year-end.
OrthoPediatrics (Nasdaq: KIDS) will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.
Investors can access a live and archived webcast on the company's Investors page in the Events & Presentations section; the replay will be available for at least 90 days.
OrthoPediatrics (Nasdaq: KIDS) announced that partner iotaMotion received FDA 510(k) clearance to expand use of the iotaSOFT® cochlear implant insertion system to patients four years and older on Feb. 3, 2026. The clearance extends access to robotic-assisted cochlear implantation for school-aged children.
Cincinnati Children’s Hospital is the first dedicated pediatric center to adopt iotaSOFT, joining over 35 U.S. cochlear implant centers and many neurotology fellowship programs that have adopted the technology. OrthoPediatrics positions this as strategic growth for its Enabling Technologies division to expand beyond orthopedics while remaining capital-light.
OrthoPediatrics (Nasdaq: KIDS) reported preliminary unaudited full year 2025 net revenue of $236.1M, up 15% vs. 2024, with domestic revenue of $186.2M (+16%) and international revenue of $49.9M (+15%). Q4 2025 preliminary revenue was $61.3M (+16% YoY), with domestic Q4 at $48.4M (+13%) and international Q4 at $12.9M (+32%). The company generated approximately $6.0–$7.0M of Q4 free cash flow and reduced full-year free cash flow usage by over 50% vs. 2024. The company received EUMDR certification for Response Spine products and related trauma and deformity devices. For 2026, OrthoPediatrics guides revenue of $262M–$266M (11%–13% growth), expects ~$10M annual set deployment and projects $25M Adjusted EBITDA.
OrthoPediatrics (Nasdaq: KIDS) announced on November 13, 2025 an expansion of its OrthoPediatrics Specialty Bracing (OPSB) portfolio with two new product launches: the PediHip™ Rigid Brace and PediHip™ Modular Abduction System.
The PediHip products, developed with pediatric hip experts, are intended to treat developmental dysplasia of the hip (DDH) and provide post-operative stabilization for children age three years and younger. OrthoPediatrics now offers 31 systems within its OPSB division and positions the PediHip portfolio alongside its Trauma & Deformity products to address the pediatric hip care continuum.
OrthoPediatrics (Nasdaq: KIDS) will participate in three investor conferences in November–December 2025: a Stifel 2025 Healthcare Conference fireside chat on Nov 13, 2025 at 1:20 pm ET; a Jefferies Global Healthcare Conference presentation in London on Nov 18, 2025 at 12:00 pm ET; and a Piper 37th Annual Healthcare Conference fireside chat on Dec 4, 2025 at 9:30 am ET.
An audio webcast of the discussions will be available on the company investor relations website and a replay will be accessible for 90 days after each event.
OrthoPediatrics (NASDAQ: KIDS) reported third quarter 2025 results for the period ended September 30, 2025, with total revenue $61.2M (up 12% YoY) and adjusted EBITDA $6.2M (up 56% YoY).
U.S. revenue was $48.7M (14% increase) and international revenue was $12.5M (6% increase). Revenue excluding 7D capital sales was $60.7M (up 17% YoY). Trauma & Deformity revenue rose 17% to $44.1M; Scoliosis revenue rose 4% to $16.3M.
GAAP diluted loss per share was $0.50; non-GAAP diluted loss per share was $0.24. Free cash flow usage improved to $3.4M (Q3 2024: $11.6M). Cash and equivalents were $59.8M as of Sept 30, 2025. Company updated full-year 2025 revenue guidance to $233.5M–$234.5M and reiterated adjusted EBITDA target of $15M–$17M.
OrthoPediatrics (Nasdaq: KIDS) announced FDA approval of the 3P Pediatric Plating Platform Small-Mini System on October 28, 2025, the company’s 6th FDA approval in 2025. The system is a variable-angle locking plate-and-screw solution for pediatric trauma and deformity surgeries with procedure-specific and utility plates in 2.0mm, 2.4mm, 2.7mm, and 3.5mm sizes.
Features include specialized instruments, streamlined tray layouts, and color-coding to enhance operating room efficiency. The Small-Mini System follows the 3P Hip System and is slated for a limited market release in early 2026.
OrthoPediatrics (Nasdaq: KIDS) will release its third quarter 2025 financial results on October 28, 2025 after market close. The company will host a conference call on October 28, 2025 at 4:30 p.m. ET to discuss results.
Investors can access a live and archived webcast via the company website on the Investors page in the Events & Presentations section. The webcast replay will be available for at least 90 days after the event.